Response of mepolizumab to corticosteroids in extreme eosinophilic bronchial asthma

The following is the abstract of "Response to corticosteroids after mepolizumab in severe eosinophilic asthma

 a randomized placebo-controlled crossover trial (MAPLE)" published in the November 2022 issue of Allergy 

In people with severe eosinophilic asthma (SEA), mepolizumab inhibits IL-5 activity and reduces both the frequency of exacerbations

and the amount of oral corticosteroids (OCS) required for renewal

Regardless of anti-IL-5 medication, some people continue to require OCS, suggesting persistent corticosteroid response mechanisms. 

 Therefore, in patients with SEA taking mepolizumab, evaluate the medical and anti-inflammatory effects of OCS.

 After 12 weeks of mepolizumab treatment for adults with EAS, we conducted a randomized, triple-blind, placebo-controlled crossover trial with prednisolone

The researchers tested the effects of prednisolone and placebo on a variety of metrics associated with allergies, including symptom severity, first class of life

To Get Complete Knowledge About Health Then Check Link